A drug developed for diabetes Alzheimer's after scientists found it "significantly reversed memory loss " in mice through a triple method of action, a study published in the journal Brain Research . The research could bring substantial improvements in the treatment of Alzheimer's disease through the use of a drug originally created to treat type 2 diabetes.
Lead researcher Professor Christian Holscher of Lancaster University in the UK said the novel treatment "holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer's disease."
Dr. Doug Brown, Director of Research and Development at Alzheimer's Society, said, "It's imperative that we explore whether drugs can be used to treat other conditions, and Alzheimer's and other forms of dementia . get promising new drugs to the people who need them. "
"Although the benefits of these 'triple agonist' drugs have so far only been found in mice, other studies with existing diabetes drugs such as liraglutide have shown a real promise for people with Alzheimer's, so further development of this work is crucial."
This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration. It combines GLP-1, GIP, and Glucagon which are all growth factors. Problems with growth factor signalling have been shown to be impaired in the brains of Alzheimer's patients.
The study used APP / PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer's. Those genes have been found in people who have a form of Alzheimer's that can be inherited. Aged transgenic mice in the advanced stages of neurodegeneration were treated.
In a maze test, learning and memory formation were much improved by the drug which also enhanced levels of a brain growth factor which protects nerve cell functioning; reduced the amount of amyloid plaques in the brain linked with Alzheimer's; reduced both chronic inflammation and oxidative stress and slowed down the rate of nerve cell loss.
Professor Holscher said, "These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that were originally developed to treat type 2 diabetes but have shown neuroprotective effects in several studies."
"Here we show that a triple triple drug receptor shows promise to a potential treatment for Alzheimer's, but in addition to the dose-response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this new drug is superior to previous ones."
Type 2 diabetes is a risk factor for Alzheimer's disease and has been implicated in the progression of the disease. Impaired insulin has been linked to cerebral degenerative processes in type 2 diabetes and Alzheimer's disease.
Insulin desensitization has also been observed in the Alzheimer's disease brain. The desensitization could play a role in the development of neurodegenerative disorders as insulin is a growth factor with neuroprotective properties.